Is ribociclib (Kaillon) a chemotherapy drug or a targeted drug and its specific positioning in clinical treatment?

Ribociclib is an oral selective CDK4/6 inhibitor that is a targeted drug rather than a traditional chemotherapy drug. Its mechanism of action is to inhibit the key CDK4 and CDK6 proteins in the cell cycle, preventing tumor cells from entering the S phase from the G1 phase, thereby inhibiting tumor proliferation. Unlike traditional chemotherapy drugs that rely on cytotoxic killing, ribociclib is a precise targeted therapy that is more selective and causes relatively little damage to normal cells.

In clinical treatment, ribociclib is mainly used for HR positive, HER2 negative advanced or metastatic breast cancer, usually in combination with endocrine therapy (such as letrozole or fulvestrant). The combination regimen has been shown in multiple key clinical trials to significantly extend progression-free survival (PFS), improve disease control rate, and is better tolerated than traditional chemotherapy. Due to its targeting mechanism, ribociclib is not a broad-spectrum cytotoxic drug, so it usually does not cause alopecia, severe nausea or severe bone marrow suppression that are common with chemotherapy, but there is still a need to pay attention to the risk of hematological toxicity and cardiac QT interval prolongation.

Ribociclib is clinically positioned as the core drug in combined endocrine therapy for patients with advanced breast cancer, especially for patients with initial treatment or pre-endocrine resistanceHR+/HER2-. For patients who are not candidates for or wish to avoid chemotherapy, ribociclib combined with endocrine therapy provides an effective and relatively low-toxic treatment option. At the same time, it is also being explored in some studies as an adjuvant treatment for early-stage breast cancer to delay the risk of disease recurrence.

In short, ribociclib is clearly a targeted drug rather than a chemotherapy drug. Its core function is to block the tumor cell cycle through precise inhibition of CDK4/6, thereby controlling tumor proliferation. Clinically, it is mainly positioned as endocrine combination therapy for HR+/HER2- advanced breast cancer. It is a modern targeted therapy with good tolerance and significant efficacy.

Keyword tags: ribociclib,CDK4/6inhibitor, breast cancer, manufacturer, global supply

Reference materials:https://go.drugbank.com/drugs/DB11730